Disclosed are oral dosage forms comprising an effective amount of mesalamine, wherein the dosage form has a dissolution profile such that greater than 5 wt % of the total weight of the mesalamine in the dosage form is released during a pH 6.0 portion of a dissolution test, the dissolution test comprising stirring in a pH 6.0 solution for 1 hour, followed by stirring in a pH 7.2 solution for an additional hour. In some embodiments, the dosage form releases less than all of the mesalamine to the right side of the colon. Release of less than all of the mesalamine dosage form to the right side of the colon may be determined by the in vitro dissolution profile of the dosage form.